Method to enhance hematopoiesis

Abstract

The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to treat a deficiency of one or more types of blood cells in a mammal, which includes administering an effective amount of TISF or of a compound that stimulates CD 4 + cells like TISF does. In one embodiment, TISF that originates from a mammalian species is administered to a mammalian subject diagnosed as having a deficiency in one or more types of blood cells.

1 . A method to stimulate production of red blood cells in a subject, wherein said subject has been diagnosed as having a less than desirable level of red blood cells, which method comprises administering to the subject an effective amount of a compound that stimulates CD4+ cells,
 wherein the compound that stimulates CD4+ cells is selected from the group consisting of IL-2, IL-4, IL-7, IL-12, anti-CD3 antibody, CD28, and superantigens.   
     
     
         2 . The method of  claim 1 , wherein said compound is a superantigen selected from the group consisting of toxic shock syndrome toxin-1 (TSST-1), streptococcal pyrogenic endotoxin (SPE), and staphylococcal enterotoxins. 
     
     
         3 . A method to stimulate production of platelets in a subject, wherein said subject has been diagnosed as having a less than desirable level of platelets, which method comprises administering to the subject an effective amount of a compound that stimulates CD4+ cells,
 wherein the compound that stimulates CD4+ cells is selected from the group consisting of IL-2, IL-4, IL-12, anti-CD3 antibody, CD28, and superantigens.   
     
     
         4 . The method of  claim 3 , wherein said compound is a superantigen selected from the group consisting of toxic shock syndrome toxin-1 (TSST-1), streptococcal pyrogenic endotoxin (SPE), and staphylococcal enterotoxins. 
     
     
         5 . A method to stimulate production of granulocytes in a subject, wherein said subject has been diagnosed as having a less than desirable level of granulocytes, which method comprises administering to the subject an effective amount of a compound that stimulates CD4+ cells,
 wherein the compound that stimulates CD4+ cells is selected from the group consisting of IL-2, IL-4, IL-7, IL-12, anti-CD3 antibody, CD28, and superantigens.   
     
     
         6 . The method of  claim 5 , wherein said compound is a superantigen selected from the group consisting of toxic shock syndrome toxin-1 (TSST-1), streptococcal pyrogenic endotoxin (SPE), and staphylococcal enterotoxins. 
     
     
         7 . A therapeutic protocol that comprises administering to a subject an amount of a compound that stimulates CD4+ cells,
 wherein the subject has a less than desirable level of at least one type of blood cells selected from red blood cells, platelets and granulocytes,   wherein the amount of said compound is effective to elevate the level of the at least one type of blood cells selected from red blood cells, platelets and granulocytes whose level in said subject is less than desirable, and   wherein the compound is selected from the group consisting of IL-2, IL-4, IL-12, anti-CD3 antibody, CD28, and superantigens.   
     
     
         8 . The therapeutic protocol of  claim 7 , wherein said subject is diagnosed as having a less than desirable level of red blood cells. 
     
     
         9 . The therapeutic protocol of  claim 7 , wherein said subject is diagnosed as having a less than desirable level of platelets. 
     
     
         10 . The therapeutic protocol of  claim 7 , wherein said subject is diagnosed as having a less than desirable level of granulocytes. 
     
     
         11 . The therapeutic protocol of  claim 7 , wherein said compound is a superantigen selected from the group consisting of toxic shock syndrome toxin-1 (TSST-1), streptococcal pyrogenic endotoxin (SPE), and staphylococcal enterotoxins. 
     
     
         12 . The therapeutic protocol of  claim 7 , wherein said subject has a less than desirable level of at least two types of blood cells selected from red blood cells, platelets and granulocytes. 
     
     
         13 . The therapeutic protocol of  claim 7 , wherein the subject has pancytopenia.